https://www.selleckchem.com/ph....armacological_epigen
25). Endothelial cell loss was comparable between both groups 33.4% versus 33.6% at 1 month (p = .97), 37.4% versus 34.9% at 3 months (p = .68) and 41.6% versus 38.3% at 6 months (p = .42) in the cefuroxime and NC groups, respectively. The rates of rebubbling, graft rejection, and cystoid macular edema were not significantly higher in the cefuroxime group. Conclusion The use of intracameral cefuroxime during simple or combined DMEK did not lead to higher graft endothelial cell loss.This study is part of a broader phenomenolog
Like
Comment
Share
